M E Gore

Summary

Affiliation: Royal Marsden Hospital
Country: UK

Publications

  1. ncbi request reprint Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study
    Ronald Bukowski
    Experimental Therapeutics Program, Cleveland Clinic Cancer Center, Cleveland, OH 44195, USA
    J Clin Oncol 20:3841-9. 2002
  2. ncbi request reprint Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment
    Viviane Hess
    Gynecology Unit, Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, UK
    J Clin Oncol 22:1040-4. 2004
  3. ncbi request reprint New drug therapies for advanced renal cell carcinoma
    Martin E Gore
    Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    Expert Rev Anticancer Ther 7:57-71. 2007
  4. pmc A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma
    J M G Larkin
    Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, UK
    Br J Cancer 96:44-8. 2007
  5. doi request reprint Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology
    M E Gore
    Department of Oncology, The Royal Marsden Hospital, London, UK
    Eur J Cancer 48:1038-47. 2012
  6. pmc Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests
    Mariëlle Ae Nobbenhuis
    Department of Gynaecological Oncology, The Institute of Cancer Research and The Royal Marsden Foundation Trust, Cotswold Road and Fulham Road, SW3 6JJ, London, UK
    Hered Cancer Clin Pract 9:11. 2011
  7. pmc Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
    Charles Swanton
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London, WC2A 3PX, UK
    Genome Med 2:53. 2010
  8. ncbi request reprint Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
    Martin E Gore
    Royal Marsden Hospital NHS Trust, London, UK
    Lancet Oncol 10:757-63. 2009
  9. pmc Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial
    Martin E Gore
    Royal Marsden Hospital NHS Trust, London, UK
    Lancet 375:641-8. 2010
  10. ncbi request reprint Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma
    Martin E Gore
    Department of Medicine, The Royal Marsden Hospital NHS Trust, London, England
    Oncology (Williston Park) 20:19-24. 2006

Collaborators

Detail Information

Publications61

  1. ncbi request reprint Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study
    Ronald Bukowski
    Experimental Therapeutics Program, Cleveland Clinic Cancer Center, Cleveland, OH 44195, USA
    J Clin Oncol 20:3841-9. 2002
    ....
  2. ncbi request reprint Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment
    Viviane Hess
    Gynecology Unit, Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, UK
    J Clin Oncol 22:1040-4. 2004
    ..Chemotherapy for mEOC is chosen according to guidelines established for EOC. The purpose of this study is to determine whether this is appropriate...
  3. ncbi request reprint New drug therapies for advanced renal cell carcinoma
    Martin E Gore
    Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    Expert Rev Anticancer Ther 7:57-71. 2007
    ....
  4. pmc A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma
    J M G Larkin
    Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, UK
    Br J Cancer 96:44-8. 2007
    ..The combination of temozolomide and lomustine in patients with brain metastases from melanoma does not demonstrate activity. The further evaluation of this combination therefore is not warranted...
  5. doi request reprint Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology
    M E Gore
    Department of Oncology, The Royal Marsden Hospital, London, UK
    Eur J Cancer 48:1038-47. 2012
    ....
  6. pmc Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests
    Mariëlle Ae Nobbenhuis
    Department of Gynaecological Oncology, The Institute of Cancer Research and The Royal Marsden Foundation Trust, Cotswold Road and Fulham Road, SW3 6JJ, London, UK
    Hered Cancer Clin Pract 9:11. 2011
    ..abstract:..
  7. pmc Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
    Charles Swanton
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London, WC2A 3PX, UK
    Genome Med 2:53. 2010
    ....
  8. ncbi request reprint Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
    Martin E Gore
    Royal Marsden Hospital NHS Trust, London, UK
    Lancet Oncol 10:757-63. 2009
    ..The primary objective of this trial was to provide sunitinib on a compassionate-use basis to trial-ineligible patients with RCC from countries where regulatory approval had not been granted...
  9. pmc Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial
    Martin E Gore
    Royal Marsden Hospital NHS Trust, London, UK
    Lancet 375:641-8. 2010
    ..We aimed to compare overall survival in patients receiving combination treatment or interferon alfa-2a...
  10. ncbi request reprint Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma
    Martin E Gore
    Department of Medicine, The Royal Marsden Hospital NHS Trust, London, England
    Oncology (Williston Park) 20:19-24. 2006
    ..Issues surrounding study endpoints and biologic efficacy markers for molecular targeted agents in RCC are discussed in this article, with a focus on results of the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGETs)...
  11. doi request reprint Sunitinib in metastatic renal cell carcinoma patients with brain metastases
    Martin E Gore
    Royal Marsden Hospital NHS Trust, London, United Kingdom
    Cancer 117:501-9. 2011
    ..Here, the authors report results for patients with baseline brain metastases participating in this global EAP...
  12. pmc Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies
    M E Gore
    Department of Medicine, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 104:399-406. 2011
    ....
  13. pmc Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study
    M J Allen
    Royal Marsden Hospital, London, UK
    Br J Cancer 83:980-5. 2000
    ..It is of particular interest that this regimen appears to have high activity in fit patients with poor prognostic features...
  14. ncbi request reprint Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval
    M E Gore
    Medical Oncology, Royal Marsden Hospital NHS Trust, London, UK
    Eur J Cancer 38:S7-12. 2002
    ..Overall response rates for all platinum-resistant and -sensitive patients were 8.3% and 32.4%, respectively. Stable disease occurred in 17 resistant and 15 sensitive patients...
  15. pmc Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma
    S R Johnston
    The Melanoma Unit, Royal Marsden NHS Trust, London, UK
    Br J Cancer 77:1280-6. 1998
    ....
  16. pmc A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma
    J M G Larkin
    Department of Renal Oncology, The Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London, SW36JJ, UK
    Br J Cancer 103:1149-53. 2010
    ..We conducted a phase I/II trial to determine the safety and efficacy of infliximab in combination with sorafenib in patients with advanced RCC...
  17. doi request reprint Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC)
    D F Kolomainen
    Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, UK
    Gynecol Oncol 125:31-6. 2012
    ..To describe the outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) so as to define the criteria for patient selection for palliative surgery...
  18. ncbi request reprint Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma
    V Hess
    Royal Marsden Hospital, London, UK
    Ann Oncol 14:638-42. 2003
    ..Toxicity can be reduced by weekly administration. We examined the tolerability of weekly paclitaxel in combination with carboplatin and doxorubicin...
  19. doi request reprint Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma
    P J Ross
    The Head and Neck Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Clin Oncol (R Coll Radiol) 21:311-4. 2009
    ..Chemotherapy is reserved for treatment of symptomatic recurrence. We evaluated the combination of epirubicin, cisplatin and protracted venous infusion 5-fluorouracil (ECF) in the management of ACC...
  20. pmc Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer
    T Eisen
    Department of Medicine, Royal Marsden Hospital, London, UK
    Br J Cancer 82:812-7. 2000
    ..No patients developed WHO grade 3 or 4 toxicity. Further studies evaluating the use of Thalidomide at higher doses as a single agent for advanced renal cancer and in combination with biochemotherapy regimens are warranted...
  21. doi request reprint A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma
    J E Ang
    Royal Marsden Hospital, London and Sutton, Surrey, UK
    Ann Oncol 20:1787-93. 2009
    ..Platinum compounds, taxanes and anthracyclines provide the major effective drug classes in the treatment of advanced and recurrent endometrial cancer and carcinosarcoma...
  22. pmc Platinum-Taxol non-cross resistance in epithelial ovarian cancer
    M E Gore
    Gynaecology Unit, Royal Marsden Hospital, London, UK
    Br J Cancer 71:1308-10. 1995
    ..These data support current strategies that involve combining Taxol with platinum compounds as first-line therapy in advanced epithelial ovarian cancer...
  23. pmc Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups
    M E Gore
    Royal Marsden Hospital, London, UK
    Br J Cancer 75:710-4. 1997
    ..Paclitaxel given at 225 mg m(-2) to patients with stage IV epithelial ovarian cancer is active, well tolerated and does not require GCSF support...
  24. ncbi request reprint The natural history and management of Merkel cell carcinoma of the skin: a review of 22 patients treated at the Royal Marsden Hospital
    P Savage
    Skin and Melanoma Unit, Royal Marsden Hospital, London, UK
    Clin Oncol (R Coll Radiol) 9:164-7. 1997
    ..To clarify the role of adjuvant postoperative radiotherapy and to establish the appropriate use of chemotherapy in metastatic spread of this rare malignancy will require further studies with multicentre cooperation...
  25. pmc Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease
    M T Seymour
    Department of Medical Oncology, St Bartholomew s Hospital, London, UK
    Br J Cancer 69:191-5. 1994
    ..It has significant toxicity which may be avoided by appropriate patient selection and an escalating-duration schedule...
  26. pmc Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo
    A L Jones
    Section of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 62:776-80. 1990
    ..The enhancement of BCNU cytotoxicity by TNF may be important if it can be translated into patients with melanoma. A randomised study is now underway to investigate the clinical potential of this observation...
  27. ncbi request reprint Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy
    D D Gibbs
    Department of Medicine, The Royal Marsden Hospital, London, England
    Drugs 61:1103-20. 2001
    ..Many agents are active in platinum-resistant disease, but uncertainties remain about the relative efficacies of each and the place of combination therapy...
  28. pmc The treatment of advanced renal cell cancer with high-dose oral thalidomide
    J Stebbing
    Department of Medical Oncology, The Royal Marsden Hospital, London SW3 6JJ, UK
    Br J Cancer 85:953-8. 2001
    ..Toxicities were of sufficient clinical significance for use of a lower and well tolerated dose of 400 mg in currently accruing studies...
  29. pmc A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily
    P Savage
    Department of Medicine, Royal Marsden Hospital, London, UK
    Br J Cancer 74:1482-6. 1996
    ..Further investigation of imiquimod as an interferon-inducing agent in cancer patients is suggested at either the lower dose levels or employing alternative dosing schedules...
  30. pmc Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit
    S Lakhani
    Section of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 61:330-4. 1990
    ..For all treatments, life table estimates of survival at 1 and 2 years were only 10% and 4% respectively...
  31. pmc A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma
    F Y Ahmed
    Department of Medicine, Royal Marsden Hospital, London, UK
    Br J Cancer 74:1109-13. 1996
    ..This study illustrates that prolonged subcutaneous IL-2 can be given safely in the outpatient setting. There was no evidence that levamisole acts as an immunomodulator in this study...
  32. pmc Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience
    M E Gore
    Royal Marsden NHS Trust, London, UK
    Br J Cancer 72:1016-9. 1995
    ..The UK and Eire experience is very similar to that of US investigators in this group of patients. Further work is required to assess the optimal use of the drug in both first- and second-line therapy...
  33. ncbi request reprint Caelyx: phase II studies in ovarian cancer
    S R Johnston
    Gynaecological Unit, Department of Medicine, Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, SW3 6JJ, London, UK
    Eur J Cancer 37:S8-14. 2001
    ..ovarian cancer together with an improved safety profile are all strongly supportive of a positive benefit-risk profile for Caelyx in the treatment of advanced ovarian cancer following failure of first-line platinum-based therapy..
  34. pmc Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response
    J A Maitland
    Section of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 61:429-33. 1990
    ....
  35. pmc A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma
    S L Morris
    Melanoma Unit, The Royal Marsden Hospital NHS Trust, 203 Fulham Road, London SW3 6JJ, UK
    Br J Cancer 91:829-33. 2004
    ..We identified that patients with RPA class 3, leptomeningeal involvement or RPA class 2 with poor prognostic index are unlikely to benefit from palliative WBRT...
  36. ncbi request reprint Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer
    E C Brockbank
    Department of Gynaecological Oncology, The Royal Marsden Hospital, London, UK
    Int J Gynecol Cancer 14:42-50. 2004
    ..Selection criteria are required to identify women who may benefit from this approach...
  37. pmc Cisplatin/carboplatin cross-resistance in ovarian cancer
    M E Gore
    Gynaecology Unit, Royal Marsden Hospital, London, UK
    Br J Cancer 60:767-9. 1989
    ..Three patients (6.5%) responded to this second treatment but these patients had no survival advantage compared to the non-responders. One responder had progressive disease on cisplatin before crossing over to carboplatin...
  38. pmc EPIC: an effective low toxicity regimen for relapsing lymphoma
    T Hickish
    Lymphoma Unit, Royal Marsden Hospital, Sutton, Surrey, London, UK
    Br J Cancer 68:599-604. 1993
    ..The EPIC regimen has equivalent activity to other reported cisplatin based regimens used in the treatment of recurrent lymphoma, but is associated with lower treatment related morbidity and mortality...
  39. pmc Phase II trial of trimelamol in refractory ovarian cancer
    I R Judson
    Section of Drug Development, Institute of Cancer Research, Royal Marsden Hospital, UK
    Br J Cancer 63:311-3. 1991
    ..5%. The main toxicity observed was nausea and vomiting, myelosuppression was minor. The role of Trimelamol in the treatment of ovarian cancer remains to be defined, but its activity is limited in refractory disease...
  40. doi request reprint Significance of tumour calcification in ovarian carcinoma
    G J C Burkill
    Department of Radiology, The Royal Marsden Hospital, London, UK
    Br J Radiol 82:640-4. 2009
    ..In conclusion, calcification tends to occur most commonly in serous cystadenocarcinomata and in tumours of lower grade. Changes in calcification cannot be used as a marker of disease response...
  41. ncbi request reprint Expression of p16, CD95, CD95L and Helix pomatia agglutinin in relapsing and nonrelapsing very thin melanoma
    L A Fearfield
    Department of Dermatology, Imperial College School of Medicine START Laboratories, Chelsea and Westminster Hospital, London, UK
    Br J Dermatol 156:440-7. 2007
    ..Most patients with very thin melanoma (Breslow thickness < 0.76 mm) are cured by surgery but 2-18% relapse locally or with distant metastases...
  42. ncbi request reprint Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma
    Chooi P Lee
    Department of Medicine, Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 24:898-903. 2006
    ..To investigate escalating doses of thalidomide compared with medroxyprogesterone in patients with metastatic renal cell carcinoma (RCC), who had either progressed after first-line immunotherapy or who were not suitable for immunotherapy...
  43. pmc Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies
    James M G Larkin
    Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    Oncologist 15:1135-46. 2010
    ..Fatigue remains a prominent toxicity with current targeted therapies. Future agents that show better selectivity and potency than current targeted therapies should help to provide better efficacy and tolerability...
  44. ncbi request reprint Mucosal malignant melanoma of the head and neck: the Marsden experience over half a century
    N W Yii
    Head and Neck Unit, The Royal Marsden NHS Trust, London, UK
    Clin Oncol (R Coll Radiol) 15:199-204. 2003
    ..Adding radiotherapy to surgery in tumours that could be radically excised did not confer any statistically significant advantage in reducing local recurrence or improving survival...
  45. ncbi request reprint A phase II trial of ZD0473 in platinum-pretreated ovarian cancer
    M E Gore
    Medical Oncology, Royal Marsden Hospital NHS Trust, London, UK
    Eur J Cancer 38:2416-20. 2002
    ..In conclusion, ZD0473 has a manageable toxicity profile and encouraging activity in platinum-sensitive ovarian cancer patients...
  46. ncbi request reprint Temsirolimus in the treatment of advanced renal cell carcinoma
    M E Gore
    Royal Marsden Hospital, Fulham Road, London, UK
    Ann Oncol 18:ix87-8. 2007
  47. ncbi request reprint Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer
    S Bishara
    Department of Gynaecological Oncology, Royal Marsden Hospital, London, UK
    Eur J Obstet Gynecol Reprod Biol 138:71-5. 2008
    ..Here we have investigated their influence on outcome in primary epithelial ovarian cancer...
  48. doi request reprint Establishing the role of cytokine therapy in advanced renal cell carcinoma
    Martin E Gore
    Royal Marsden Hospital, London, UK
    BJU Int 101:1063-70. 2008
    ..The European oncology community has lost one of its giants and I, a dear friend. This manuscript is dedicated to the memory of Professor Pieter de Mulder...
  49. ncbi request reprint Imaging in metastatic renal cell carcinoma
    Nyree Griffin
    Department of Diagnostic Imaging, Royal Marsden Hospital, 203 Fulham Rd, London SW3 6JJ, United Kingdom
    AJR Am J Roentgenol 189:360-70. 2007
    ..CONCLUSION: Imaging is likely to play an increasing role in the management, diagnosis, and monitoring of response to treatment of metastatic renal cell carcinoma...
  50. pmc Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC)
    K J Palmer
    Department of Immunology, University College London, Windeyer Institute of Medical Science, and Skin and Melanoma Unit, The Royal Marsden Hospital, London, UK
    Clin Exp Immunol 119:412-8. 2000
    ..These results suggest that the clinical effects of IFN-alpha in melanoma patients may be immune-mediated...
  51. pmc The impact of computed tomography and ultrasonography on the management of patients with carcinoma of the ovary
    M E Gore
    Department of Medicine, Royal Marsden Hospital, London, UK
    Br J Cancer 60:751-4. 1989
    ..In view of current financial restrictions in health care, clinicians should be more selective in the use of these imaging techniques. Furthermore, we recommend that similar prospective studies are performed for other clinical situations...
  52. ncbi request reprint Mucinous ovarian cancer
    M L Harrison
    Department of Medicine, Royal Marsden Hospital, London, United Kingdom
    Int J Gynecol Cancer 18:209-14. 2008
    ..For all mucinous tumors of the ovary, establishing primary as opposed to metastatic cancers is important. Clinical presentation, tumor markers, histologic, and immunohistochemical features are helpful in distinguishing most cases...
  53. ncbi request reprint Drug insight: advances in renal cell carcinoma and the role of targeted therapies
    James M G Larkin
    Royal Marsden Hospital, London, UK
    Nat Clin Pract Oncol 4:470-9. 2007
    ..Additional studies are needed to determine the optimum utilization of these agents at the appropriate stage of disease and in the best combinations for maximal clinical benefit...
  54. pmc Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials
    Michelle L Harrison
    Department of Gynaecology, The Royal Marsden Hospital, London, UK
    Gynecol Oncol 106:469-75. 2007
    ....
  55. pmc A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer
    D D Gibbs
    Department of Medicine, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 86:1379-84. 2002
    ....
  56. doi request reprint Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities
    R Sinha
    Department of Dermatology, Chelsea and Westminster Hospital, London SW10 9NH, U K
    Br J Dermatol 167:987-94. 2012
    ....
  57. ncbi request reprint Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy?
    Desiree F Kolomainen
    Gynaecology Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    J Clin Oncol 21:3113-8. 2003
    ..We have previously reported the cases of patients managed with a policy of observation only. We now present the salvage rate for the patients in that study who experienced relapse...
  58. doi request reprint "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations
    David S P Tan
    Gynaecological Oncology and Cancer Genetics Units, Royal Marsden Hospital, London, UK
    J Clin Oncol 26:5530-6. 2008
    ....
  59. ncbi request reprint Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence
    Desiree F Kolomainen
    Gynaecology Unit, Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 20:982-6. 2002
    ..We present the Royal Marsden Hospital experience of cerebral metastases from primary epithelial ovarian carcinoma (EOC) over the last 20 years and examine the evidence for an increasing incidence of EOC metastasizing to this site...
  60. doi request reprint First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series
    Roshan Agarwal
    Section of Medicine, The Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, London, UK
    Eur J Cancer 46:2020-6. 2010
    ..Here we present the results of the sixth study, and an analysis of the overall series...
  61. ncbi request reprint Biochemotherapy for advanced melanoma
    Ulrich Keilholz
    Department of Medicine III Hematology, Oncology, and Transfusion Medicine, University Hospital Benjamin Franklin, Free University of Berlin, Berlin, Germany
    Semin Oncol 29:456-61. 2002
    ..So far, none of the approaches has been proven to confer a survival benefit and thus the uniform desire is to include as many patients as possible in controlled clinical trials...